Abcam, ab120138, Nimodipine, L-type Ca2+ channel blocker

Size: 100mg / 500mg
MW 418.4 Da, Purity >98%. L-type Ca2+ channel blocker. Potent cerebrovasodilator. Cognitive enhancer. More lipophilic than nifedipine (ab120135).
Key facts
CAS number:66085-59-4,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:418.4 Da,
Molecular formula:C21H26N2O7,
PubChem:4497,
Nature:Synthetic,
Solubility:Soluble in DMSO to 100 mMSoluble in ethanol to 10 mM,
Biochemical name:Nimodipine,
Biological description:L-type Ca2+ channel blocker. Potent cerebrovasodilator. Cognitive enhancer. More lipophilic than nifedipine (ab120135).,
Canonical smiles:CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,
InChi:InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3,
InChiKey:UIAGMCDKSXEBJQ-UHFFFAOYSA-N,
IUPAC Name:3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Product details:
Nimodipine is light sensitive and it is recommended that the compound is protected from light.

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-Ambient, Appropriate long-term storage conditions-Ambient, Storage information-The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Parkin also known as PARK2 is a protein with a mass of approximately 52 kDa. This protein functions as an E3 ubiquitin ligase and it is an important part of the ubiquitin-proteasome system which tags proteins for degradation. Parkin is expressed across several tissues with significant levels found in the brain particularly in dopaminergic neurons. The progesterone receptor weighing around 98 kDa binds progesterone and activates transcription of target genes. It is expressed in reproductive tissues like the uterus and breast. CACNA1C (Cav1.2) forms an L-type calcium channel subunit and weighs around 260 kDa. It is found in the heart and brain. Cannabinoid Receptor I known as CB1 weighing about 52 kDa is a G-protein coupled receptor highly expressed in the central nervous system.
Biological function summary
These targets show distinct roles in cellular functions. Parkin participates in mitochondrial quality control often forming a complex with PINK1 to mediate mitophagy. The progesterone receptor regulates genes involved in reproductive tissue development and maintenance. CACNA1C plays a pivotal role in calcium entry into cells influencing cardiac muscle contraction. Cannabinoid Receptor I inhibits adenylate cyclase affecting neurotransmitter release. Cytochrome P450 1A2 and 3A4/CYP3A4 perform important functions in drug metabolism. These enzymes contribute to the oxidative metabolism of a variety of substrates. Maxi Potassium channel alpha/SLO and its beta subunits like KCNMB1 affect neuron excitability by conducting potassium ions. TDP1 repairs DNA single-strand breaks. The adenosine A3 receptor influences anti-inflammatory pathways.
Pathways
Parkin and related proteins such as Ubiquitin C are involved in the ubiquitin-dependent catabolic pathway correlating with the autophagy process for cellular quality control. The progesterone receptor takes part in the steroid hormone signaling pathway working alongside estrogen receptors for gene expression control. The calcium signaling pathway includes CACNA1C and closely associates with other calcium channels like RyR2. Cannabinoid Receptor I aligns with the endocannabinoid signaling pathway. Cytochrome P450 isoenzymes CYP1A2 and CYP3A4 interact in the xenobiotic metabolism pathway involving substrates like drugs and carcinogens. Maxi potassium channel proteins regulate neural signaling pathways.
Parkin mutations are implicated in autosomal recessive juvenile Parkinson's disease with PINK1 as a related protein. Mutations in the progesterone receptor can result in reproductive system disorders including certain breast cancers closely linked to estrogen receptor pathways. Variants in CACNA1C associate with disorders like Timothy syndrome which affects the heart and brain. Cannabinoid Receptor I disruption can influence neuropsychiatric conditions such as pharmacologically targeting this receptor impacts alleviation of symptoms in schizophrenia. Cytochrome P450 enzymes like CYP3A4 alterations can contribute to adverse drug reactions. Dysfunctions in the maxi potassium channels relate to epilepsy and other neural disorders with KCNMB1 being another contributing factor.